Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA?
Roberta Rocca
1
,
Carmine Talarico
1
,
Federica Moraca
1
,
Giosuè Costa
1
,
Isabella Romeo
1
,
Francesco Ortuso
1
,
Stefano Alcaro
1
,
Anna Artese
1
1
Laboratory of Medicinal Chemistry; Department of Health Sciences; University of Catanzaro; Catanzaro Italy
|
Publication type: Journal Article
Publication date: 2017-06-06
scimago Q2
wos Q2
SJR: 0.689
CiteScore: 5.6
Impact factor: 3.3
ISSN: 17470277, 17470285
PubMed ID:
28459507
Organic Chemistry
Drug Discovery
Biochemistry
Pharmacology
Molecular Medicine
Abstract
The pyridostatin (PDS) represents the lead compound of a family of G-quadruplex (G4) stabilizing synthetic small molecules based on a N,N'-bis(quinolinyl)pyridine-2,6-dicarboxamide scaffold. Its mechanism of action involves the induction of telomere dysfunction by competing for binding with telomere-associated proteins, such as human POT1. Recently, through a template-directed "in situ" click chemistry approach, a PDS derivative, the carboxypyridostatin (cPDS), was discovered. It has the peculiarity to exhibit high molecular specificity for RNA over DNA G4, while PDS is a good generic RNA and DNA G4-interacting small molecule. Structural data on the binding modes of these compounds are not available, and the selectivity mode of cPDS toward TERRA G4 is unknown too. Therefore, this work is aimed at rationalizing the selectivity of cPDS versus TERRA G4 by means of molecular dynamics and docking simulations, coupled to better understand the binding mode of these compounds to telomeric G4 structures. The comprehensive analysis of cPDS binding mode and its conformational behavior demonstrates the importance of the ligand conformation properties coupled with a remarkable solvation contribution. This work is expected to provide valuable clues for further rational design of novel and selective TERRA G4 binders.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Pharmaceuticals
2 publications, 6.06%
|
|
|
Nucleic Acids Research
2 publications, 6.06%
|
|
|
Archiv der Pharmazie
2 publications, 6.06%
|
|
|
Journal of Computational Biophysics and Chemistry
1 publication, 3.03%
|
|
|
Cancers
1 publication, 3.03%
|
|
|
International Journal of Molecular Sciences
1 publication, 3.03%
|
|
|
Molecules
1 publication, 3.03%
|
|
|
Nature Structural and Molecular Biology
1 publication, 3.03%
|
|
|
Journal of Experimental and Clinical Cancer Research
1 publication, 3.03%
|
|
|
Biochimica et Biophysica Acta - General Subjects
1 publication, 3.03%
|
|
|
Wiley interdisciplinary reviews. RNA
1 publication, 3.03%
|
|
|
Chemical Biology and Drug Design
1 publication, 3.03%
|
|
|
Angewandte Chemie - International Edition
1 publication, 3.03%
|
|
|
Angewandte Chemie
1 publication, 3.03%
|
|
|
Exploration
1 publication, 3.03%
|
|
|
Journal of Physical Chemistry B
1 publication, 3.03%
|
|
|
European Journal of Medicinal Chemistry
1 publication, 3.03%
|
|
|
RNA Technologies
1 publication, 3.03%
|
|
|
Life Sciences
1 publication, 3.03%
|
|
|
International Journal of Biological Macromolecules
1 publication, 3.03%
|
|
|
Nature Computational Science
1 publication, 3.03%
|
|
|
Methods in Molecular Biology
1 publication, 3.03%
|
|
|
Chemistry - A European Journal
1 publication, 3.03%
|
|
|
Structure
1 publication, 3.03%
|
|
|
RNA
1 publication, 3.03%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
6
7
8
9
|
|
|
Wiley
9 publications, 27.27%
|
|
|
MDPI
5 publications, 15.15%
|
|
|
Springer Nature
5 publications, 15.15%
|
|
|
Elsevier
5 publications, 15.15%
|
|
|
Oxford University Press
2 publications, 6.06%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 6.06%
|
|
|
World Scientific
1 publication, 3.03%
|
|
|
American Chemical Society (ACS)
1 publication, 3.03%
|
|
|
1
2
3
4
5
6
7
8
9
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
33
Total citations:
33
Citations from 2024:
9
(27.27%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Rocca R. et al. Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA? // Chemical Biology and Drug Design. 2017. Vol. 90. No. 5. pp. 919-925.
GOST all authors (up to 50)
Copy
Rocca R., Talarico C., Moraca F., Costa G., Romeo I., Ortuso F., Alcaro S., Artese A. Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA? // Chemical Biology and Drug Design. 2017. Vol. 90. No. 5. pp. 919-925.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1111/cbdd.13015
UR - https://doi.org/10.1111/cbdd.13015
TI - Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA?
T2 - Chemical Biology and Drug Design
AU - Rocca, Roberta
AU - Talarico, Carmine
AU - Moraca, Federica
AU - Costa, Giosuè
AU - Romeo, Isabella
AU - Ortuso, Francesco
AU - Alcaro, Stefano
AU - Artese, Anna
PY - 2017
DA - 2017/06/06
PB - Wiley
SP - 919-925
IS - 5
VL - 90
PMID - 28459507
SN - 1747-0277
SN - 1747-0285
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2017_Rocca,
author = {Roberta Rocca and Carmine Talarico and Federica Moraca and Giosuè Costa and Isabella Romeo and Francesco Ortuso and Stefano Alcaro and Anna Artese},
title = {Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA?},
journal = {Chemical Biology and Drug Design},
year = {2017},
volume = {90},
publisher = {Wiley},
month = {jun},
url = {https://doi.org/10.1111/cbdd.13015},
number = {5},
pages = {919--925},
doi = {10.1111/cbdd.13015}
}
Cite this
MLA
Copy
Rocca, Roberta, et al. “Molecular recognition of a carboxy pyridostatin toward G-quadruplex structures: Why does it prefer RNA?.” Chemical Biology and Drug Design, vol. 90, no. 5, Jun. 2017, pp. 919-925. https://doi.org/10.1111/cbdd.13015.